Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723274 | 0.88 | CTSS (0.39) | HPGDTHRBTDP1LMNATSHR | |
| SCHEMBL2851650 | 0.80 | TSHR (0.63) | HPGDLMNATSHRRECQL | |
| SCHEMBL2854437 | 0.78 | LMNA (0.64) | HPGDTDP1LMNAPOLB | |
| SCHEMBL2858151 | 0.77 | KMT2A (0.52) | HPGDTDP1LMNARECQLPOLB | |
| SCHEMBL2852748 | 0.77 | GRM5 (0.40) | HPGDTHRBTDP1LMNAGRM5 | |
| SCHEMBL934619 | 0.77 | HPGD (0.59) | HPGDHDAC8HDAC6POLB | |
| SCHEMBL2849993 | 0.75 | USP2 (0.64) | HPGDTDP1LMNATSHRRECQL | |
| SCHEMBL2857253 | 0.75 | ALDH1A1 (0.47) | HPGDLMNA | |
| SCHEMBL9839814 | 0.74 | EPHX2 (0.64) | HPGD | |
| SCHEMBL9840800 | 0.74 | EPHX2 (0.64) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | claimed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | HPGD 1422/4885THRB 553/4885TDP1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.